Native Methylation Sequencing for Detection and Monitoring of Alzheimer’s Disease, Parkinson’s and ALS

Presented at the American Academy of Neurology (AAN) Conference

Objective

To evaluate the clinical potential of our neuronal cfDNA cell of origin classifier in identifying and distinguishing neurodegenerative disease.

Background

Alzheimer’s disease (AD) is the most common neurodegenerative disorder, yet current diagnostics remain impractical for early, presymptomatic screening. As a result, diagnosis often occurs late in the disease course, when treatment options are limited. Blood-based assays of neuropathology and neurodegeneration, while less invasive, lack the regional and cell-type specificity needed for precise characterization to guide further diagnostic testing.

Circulating cell-free DNA (cfDNA) released from dying neurons offers a promising alternative. cfDNA retains the methylation signatures of its cellular origin, providing cell-type-specific resolution of neurodegeneration with broad applicability to other diseases marked by selective neurodegeneration.‍

View the details on aan.com